Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-126 · 5 trials · 3 indications
Rater based interview
Rater based interview
An assessment tool which focuses on cognitive function and memory
| Arm | Type | Description |
|---|---|---|
| ABT-126 Low Dose | EXPERIMENTAL | ABT-126 Low Dose |
| ABT-126 High Dose | EXPERIMENTAL | ABT-126 High Dose |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| ABT-126 Middle Dose | EXPERIMENTAL | ABT-126 Middle Dose |
| sugar pill | PLACEBO_COMPARATOR | Placebo |
| ABT-126 Dose 1 | EXPERIMENTAL | - |
| ABT-126 Dose 2 | EXPERIMENTAL | - |
| A. Sugar Pill | PLACEBO_COMPARATOR | - |
| B. ABT-126 | EXPERIMENTAL | - |
| C. ABT-126 | EXPERIMENTAL | - |
| D. donepezil | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-126 | DRUG | ABT-126 Low Dose |
| Placebo | DRUG | Placebo |
| donepezil | DRUG | Active comparator intervention |
Inclusion Criteria: * Has a current Diagnostic and Statistical Manual of Mental Disorders-, 4th Edition, Text Revision (DSM-IV-TR) diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview (M.I.N.I.). * Is clinically stable while receiving a regimen of one or two all...
Top 20 of 30 competitors
ABT-126 is an investigational small molecule developed by AbbVie Inc. (ticker ABBV) for neurological conditions. It has been studied in Phase 2 clinical trials for Alzheimer's disease and for cognitive deficits in schizophrenia. It is not an approved therapy and remains in clinical development.
ABT-126 targets CHRNA7, the alpha-7 nicotinic acetylcholine receptor. It acts as an agonist at this receptor. CHRNA7 is a ligand-gated ion channel involved in cholinergic signaling, and agonism of this target has been explored as an approach in cognitive impairment associated with neurological and psychiatric conditions.
ABT-126 has been studied for Alzheimer's disease and for cognitive deficits in schizophrenia. Its Phase 2 program included a trial in mild to moderate Alzheimer's disease patients on stable doses of acetylcholinesterase inhibitors, and trials in adults with schizophrenia or cognitive deficits in schizophrenia. It is investigational and not approved for any use.
ABT-126 is developed by AbbVie Inc., which trades under the ticker ABBV. AbbVie sponsored the Phase 2 clinical program evaluating the compound in Alzheimer's disease and in cognitive deficits in schizophrenia.
ABT-126 is in Phase 2 development. All of its recorded trials are Phase 2 studies, and all are completed, with no active trials ongoing. The program covered Alzheimer's disease and cognitive deficits in schizophrenia. ABT-126 is investigational and has not been approved by the FDA.
ABT-126 was evaluated in completed Phase 2 trials including NCT01678755 and NCT01655680 in cognitive deficits in schizophrenia, NCT01549834 in mild to moderate Alzheimer's disease, and NCT01095562 in cognitive deficits in adult subjects with schizophrenia. These randomized, double-blind, placebo-controlled studies enrolled participants across the United States, Russia, the United Kingdom, Canada, France, Germany, Greece, and South Africa.